Cancer Biology and Evolution Program Metrics

View the clinical trials, grants and publications from the Cancer Epidemiology Program.

Clinical Trials
CLINICAL TRIAL 16480
Radiomics: A Prospective Study of Outcome in Lung Cancer
Condition: Multiple
Intervention:

CLINICAL TRIAL 18613
Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Condition: Sarcoma
Intervention: Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); gemcitabine ()

CLINICAL TRIAL 18752
ACTION Trial- Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I)
Condition: Neurologic Oncology
Intervention: Autologous Dendritic Cells (); Autologous Lymphocyte Infusion (); Hematopoietic Progenitor Cells (); Temodal (Temozolomide); Temozolomide ()

CLINICAL TRIAL 19365
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) with and without Topotecan and Cyclophosphamide in Patients with Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Condition: Sarcoma
Intervention: SP-2577 ()

CLINICAL TRIAL 19579
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy Fractionation for Patients with HPV+ Oropharyngeal Cancers.
Condition: Head & Neck
Intervention:

CLINICAL TRIAL 19748
Phase II Randomized Trial of Radiotherapy with Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients with Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN Trial)
Condition: Head & Neck
Intervention: Pembrolizumab (Keytruda); cisplatin ()

CLINICAL TRIAL 20094
EDRN Prostate MRI Biomarker Study and Reference Set
Condition: Multiple
Intervention:

CLINICAL TRIAL 20282
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16 Positive, Non-Smoking Associated Oropharyngeal Cancer
Condition: Head & Neck
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); cisplatin ()

CLINICAL TRIAL 20339
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Condition: Sarcoma
Intervention: Actinomycin D (Dactinomycin); Adriamycin (doxorubicin); Ifosfamide (); Navelbine (Vinorelbine); Radiotherapy (); Vincristine (); Vinorelbine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); etoposide ()

CLINICAL TRIAL 20490
Keystroke: A Randomized Phase II Study of Pembrolizumab (Keytruda) Plus Stereotactic Re-irradiation versus SBRT Alone For Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Condition: Head & Neck
Intervention: Pembrolizumab (Keytruda)

CLINICAL TRIAL 21266
Gut Metabolome-Can it be Developed As A Biomarker of Response to Immunotherapy in Metastatic Renal Cell Cancer
Condition: Genitourinary
Intervention:

CLINICAL TRIAL 50401
Creation of Cell Lines and Corresponding DNA and RNA Analysis from Acral Lentiginous Malignant Melanoma
Condition: Cutaneous
Intervention:

Grants
  • Sunshine Project-2016-2021
    Sponsor: National Pediatric Cancer Foundation
    PI:Reed, D.
  • Causes and Consequences of Acid pH in Tumors
    Sponsor: Nat Institutes of Health
    PI:Gillies, R.
  • Radiomics of NSCLC
    Sponsor: Nat Institutes of Health
    PI (Contact):Gillies, R.,PI (MPI):Schabath, M.
  • Cancer as a Complex Adaptive System
    Sponsor: Nat Institutes of Health
    PI (Contact):Gatenby, R.,PI (MPI):Gillies, R.,PI (MPI):Anderson, A.
  • Cancer as a Complex Adaptive System - FIU Diversity Supplement - Stimphill
    Sponsor: Nat Institutes of Health
    PI (Contact):Gatenby, R.
  • Moffitt PSOC: Cancer as a Complex Adaptive System - USF Diversity Supplement-Pressley
    Sponsor: Nat Institutes of Health
    PI (Contact):Gatenby, R.
  • Moffitt PSOC: Cancer as a Complex Adaptive System - Mayo Diversity Supplement - DeLeon
    Sponsor: Nat Institutes of Health
    PI:Gatenby, R.
  • Cancer as a Complex Adaptive System - Mayo Diversity Supplement - Jackson
    Sponsor: Nat Institutes of Health
    PI (Contact):Gatenby, R.
  • The Eco-Evolutionary Dynamics of Small Metastatic Population in Treatment Strategies for Prevention and Cure
    Sponsor: Nat Institutes of Health
    PI (Contact):Gatenby, R.,PI (MPI):Anderson, A.,PI (MPI):Gillies, R.
  • Cellular, Molecular and Quantitative Imaging Analysis of Suspicious Screening-Detected Lung Nodules
    Sponsor: Vanderbilt University Medical Center
    PI:Gillies, R.
  • Intrinsic Disorder Controls the Function of p53 and Other Cancer-assocoiated IDPs
    Sponsor: Univ of South Florida
    PI (MPI):Chen, J.
  • Function and Regulation of MDMX Intra-molecular Interactions
    Sponsor: Nat Institutes of Health
    PI:Chen, J.
  • Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments
    Sponsor: Vanderbilt University
    PI (MPI):Rejniak, K.
  • Multi-Scale Modeling of Bone Environment Responses to Metastatic Prostate Cancer
    Sponsor: Nat Institutes of Health
    PI (Contact):Basanta Gutierrez, D.,PI (MPI):Lynch, C.
  • Targeting CD44-Mediated Calcium Homeostasis for the Treatment of Relapsed Myeloma
    Sponsor: West Virginia University Research Corporation
    PI:Silva, A.
  • Identification of Non-Coding RNAs to Therapeutically Target Undruggable Pathways in Metastatic Lung Adenocarcinma and Squamous Cell Carcinoma
    Sponsor: Nat Institutes of Health
    PI:Flores, E.
  • MicroRNA Targets for Chemoprevention of Squamous Cell Carcinoma
    Sponsor: Nat Institutes of Health
    PI:Tsai, K.
  • Developing Chemical Probes for Oncogenic Signaling Pathways
    Sponsor: Nat Institutes of Health
    PI:Lawrence, H.
  • Year 3 of DOS47 (Cecam6-Targeted Urease) in Combination with Checkpoint Blockade
    Sponsor: Helix Biopharma Corp
    PI:Gillies, R.,CO-PI:Ibrahim Hashim, A.
  • Targeting the Lipogenic Phenotype Induced by Extracellular Acidosis in Breast Cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Gillies, R.
  • Investigation of NRF2-Dependent Metabolic Liabilities
    Sponsor: Nat Institutes of Health
    PI:DeNicola, G.
  • Investigation of NRF2-Dependent Metabolic Liabilities
    Sponsor: Nat Institutes of Health
    PI:DeNicola, G.
  • Mesenchymal Stem Cell Control of Metastatic Prostate Cancer Cell Evolution and Therapy Resistance in the Bone Microenvironment
    Sponsor: US Army
    PI:Lynch, C.
  • Eco-Evolutionary Dynamics of NSCLC to Immunotherapy: Response and Resistance
    Sponsor: Nat Institutes of Health
    PI (Contact):Anderson, A.,PI (MPI):Gatenby, R.
  • Effects of Extracellular Vesicles on MiRNA Activity in the Skin
    Sponsor: Nat Institutes of Health
    PI:Tsai, K.
  • Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer
    Sponsor: Nat Institutes of Health
    PI (Contact):Enderling, H.,PI (MPI):Gatenby, R.
  • Using the ESC-GEMM Approach to Study Mucosal Melanoma In-Vivo
    Sponsor: Melanoma Research Foundation
    PI:Karreth, F.
  • Perturbing the Evolutionary Drivers of Targeted Therapy Resistance in NSCLC
    Sponsor: Amer Cancer Society
    PI:Marusyk, A.
  • Local and Systemic Control of Multiple Myeloma Colonization and Growth by MMP-13
    Sponsor: Nat Institutes of Health
    PI:Lynch, C.
  • Applying Genomic Dosimeters of UV Damage for Skin cancer Risk Prediction
    Sponsor: Nat Institutes of Health
    PI:Tsai, K.
  • Imaging Acidosis and Immune Therapy in PDAC
    Sponsor: Nat Institutes of Health
    PI (Contact):Gillies, R.,PI (MPI):Pilon-Thomas, S.
  • KC180036-Modeling Spatial Ecology in Clear Cell Renal Cell Carcinoma Model: A Novel Tool to Support Drug Sequencing Decisions
    Sponsor: US Army
    PI:Manley, B.
  • Pilot Studies to incorporate a Radiomics-Enabled Research and Tumor Response Assessment Tracking Pipeline Within the Normal Clinical Workflow of the Moffitt Radiology Department.
    Sponsor: HealthMyne
    PI:Feuerlein, S.
  • Using Clonal and Non-Clonal UV Signature Mutations to Predict Skin Cancer Risk
    Sponsor: Nat Institutes of Health
    PI:Tsai, K.
  • KC180139-Deciphering the Role of EGFR Splice Variants and Tumor-Immune Microenvironment in Renal Cell Carcinoma
    Sponsor: US Army
    PI:Manley, B.
  • Therapeutic strategies for KEAP1/NRF2 mutant lung cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:DeNicola, G.
  • (00007009) Mechanisms of Radioresistance and Strategies for Radiosensitization in OCCC
    Sponsor: Nat Institutes of Health
    PI:Mo, Q.
  • Anti-tumor Potential of Temperature-Sensitive p53 Mutants
    Sponsor: Nat Institutes of Health
    PI:Chen, J.,CO-PI:Mann, M.
  • Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach
    Sponsor: Nat Institutes of Health
    PI (Contact):Lynch, C.,PI (MPI):Basanta Gutierrez, D.
  • Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy
    Sponsor: Nat Institutes of Health
    PI (Contact):Enderling, H.,PI (MPI):Pilon-Thomas, S.
  • Exploiting Ecology and Evolution to Prevent Therapy Resistance in EGFR-Driven Lung Cancer
    Sponsor: Nat Institutes of Health
    PI:Marusyk, A.
  • Validation of Prostate Cancer Stem Cell Model in First and Second Line Hormone Therapy
    Sponsor: Jayne Koskinas & Ted Giovanis Foundation for Health Policy
    PI:Enderling, H.
  • NRG Oncology Network Group Operations Center
    Sponsor: Nat Institutes of Health
    PI:Wuthrick, E.
  • EDRN Prostate MRI Biomarker Study and Reference Set
    Sponsor: Nat Institutes of Health
    PI (Contact):Pow-Sang, J.,CO-PI:Balagurunathan, Y.
  • Novel arginine-methylation mediated regulation of YAP1 in K-Ras mutant lung adenocarcinomas
    Sponsor: Nat Institutes of Health
    PI:Saha, B.
  • A clone's genomic stability as biomarker of its DNA-damage resilience
    Sponsor: Nat Institutes of Health
    PI:Andor, N.
  • Radiomics and Pathomics to Predict Upstaging of DCIS
    Sponsor: Nat Institutes of Health
    PI (Contact):Gillies, R.,PI (MPI):Niell, B.
  • Targeted degradation of RNAs by using small molecules
    Sponsor: Nat Institutes of Health
    PI:Cleveland, J.
  • Tumor and Metastatic Collagen Microenvironments: Divergent Targeting Approaches
    Sponsor: Nat Institutes of Health
    PI:Mo, Q.
  • Targeting Heme Dependency in Leukemia
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Reuther, G.
  • Targeting TBK1 and CARM1 to combat lung adenocarcinoma
    Sponsor: US Army
    PI:Chellappan, S.
  • CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
    Sponsor: Nat Institutes of Health
    PI:Chellappan, S.
  • Splice Ablation Kinase Inhibition (SAKI) of Receptor Tyrosine Kinases
    Sponsor: US Army
    PI:Robinson, T.
  • Disrupting Resistance to Targeted Therapies in NSCLC with Evolutionary Informed Therapies
    Sponsor: US Army
    PI:Marusyk, A.
  • Incyte/Moffitt Master Research Agreement
    Sponsor: Incyte, Inc.
    PI:Reuther, G.
  • Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Reed, D.
  • Impact of Stromal Architecture on the Response of Lung Cancers to Targeted Therapies
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Marusyk, A.,CO-PI:Altrock, P.,CO-PI:Basanta Gutierrez, D.
  • Discovery of p53 inhibitors for reducing toxicity of chemotherapy
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Chen, J.
  • Identifying Metabolic Vulnerabilities in Lung Cancer
    Sponsor: Nat Institutes of Health
    PI (Contact):Flores, E.,PI (MPI):Haura, E.,Core PI/Director:Fridley, B.,Core PI/Director:Cress, D.,Core PI/Director:Koomen, J.,Project PI:DeNicola, G.,Project PI:Rodriguez, P.,Project PI:Cleveland, J.
  • Compartmentalized and Systemic Interactions of the Skin Microbiome in Cancer Immunotherapy Response
    Sponsor: Leo Foundation - Netherlands
    PI:Tsai, K.
  • COMMITTEE LEADERSHIP: NIH National Clinical Trials Network (NCTN) Grant (2U10CA 180886)
    Sponsor: Nat Institutes of Health
    Project PI:Reed, D.
  • Metabolic basis of the NADPH-independent disulfide reductase system in mouse liver
    Sponsor: Nat Institutes of Health
    PI (MPI):DeNicola, G.
  • Molecular mechanisms of innate immune suppression by the HPV oncoprotein E6
    Sponsor: Univ of South Florida
    PI:Binning, J.
  • Building the Osteosarcoma Data Commons
    Sponsor: Rally Foundation
    PI:Reed, D.
  • Disrupting Microenvironment-Mediated Tumor Repopulation Dynamics During Therapy to Improve Cure Rates in Triple Negative Breast Cancer
    Sponsor: Florida Breast Cancer Foundation
    PI:Marusyk, A.,CO-PI:Basanta Gutierrez, D.
  • Direct Control of the human CMG Helicase by Myc and Rb
    Sponsor: Nat Institutes of Health
    PI:Alexandrow, M.
  • STUDY CHAIRNIH PEDIATRIC EARLY PHASE CLINICAL TRIALS NETWORK (PEP-CTN) GRANT(UM1CA228823) SUCCESSOR TO NIH PHASE I GRANT (2UM1CA097452); COG protocol PEPN1924
    Sponsor: Nat Institutes of Health
    PI:Reed, D.
  • Overcoming the inefficacy of ruxolitinib in myeloproliferative neoplasm patients bytargeting the SHP2 tyrosine phosphatase
    Sponsor: Moffitt Cancer Center
    PI (Contact):Reuther, G.
  • Simulating the effect of photoimmunotherapy on the ovarian cancer immune ecosystem
    Sponsor: Ocala Royal Dames
    PI:Enderling, H.
  • Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms
    Sponsor: Nat Institutes of Health
    PI:Reuther, G.
  • Propionate metabolism as an essential metabolic adaptation for tumor progression
    Sponsor: Nat Institutes of Health
    PI:Gomes, A.
  • iGEMMs: Using Chimeras to Study Immune Cell Functions in Autochthonous Melanomas
    Sponsor: Moffitt Cancer Center
    PI:Karreth, F.,CO-PI:Adeegbe, D.
  • Interrogating NAD+ synthetic pathways in lung cancer cells
    Sponsor: Moffitt Cancer Center
    PI (Contact):DeNicola, G.
  • Eco-Evolutionary Drivers of Clonal Dynamics During UV-Induced Skin Carcinogenesis (PQ3)
    Sponsor: Nat Institutes of Health
    PI (Contact):Tsai, K.,PI (MPI):Brown, J.
  • Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
    Sponsor: Nat Institutes of Health
    PI (Contact):Rejniak, K.,PI (MPI):Pilon-Thomas, S.
  • An Assessment of SOS1 inhibitors in MPN
    Sponsor: Revolution Medicines Inc
    PI:Reuther, G.
  • Chromosome 1q ceRNAs in melanoma progression and metastasis
    Sponsor: Nat Institutes of Health
    PI:Karreth, F.
  • St of FL Appropriation-Lung CoE Developmental Funds
    Sponsor: State of Florida
    PI (Contact):Cleveland, J.,PI (MPI):Haura, E.
  • St of FL Appropriation-CMRC Developmental Funds
    Sponsor: State of Florida
    PI (Contact):Cleveland, J.,PI (MPI):Smalley, K.
  • St of FL Appropriation-CIRC Developmental Funds
    Sponsor: State of Florida
    PI (Contact):Cleveland, J.,PI (MPI):Giuliano, A.
  • Elucidate the Tumor Suppressive Function of BACH2 in Melanoma
    Sponsor: Moffitt Cancer Center
    PI:Karreth, F.
  • Medical Imaging and Data Resource Center (MIDRC) for Rapid Response to COVID-19 Pandemic
    Sponsor: Nat Institutes of Health
    PI:El Naqa, I.
  • Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy
    Sponsor: Nat Institutes of Health
    PI:El Naqa, I.
  • Investigation of the Aberrant Epidermal Growth Factor Receptor Splicing Proteome to Determine Drug Repurposing Strategies for ccRCC
    Sponsor: Kidney Cancer Association (KCA)
    PI:Manley, B.
  • Combined Radiation Acoustics and Ultrasound Imaging for Real-Time Guidance in Radiotherapy
    Sponsor: Nat Institutes of Health
    PI:El Naqa, I.
  • Assessing the role of TROLLs as markers of response to chemotherapy in TNBCs
    Sponsor: APIS Assay Technologies
    PI:Flores, E.
  • Optimal Decision Making in Radiotherapy Using Panomics Analytics
    Sponsor: Nat Institutes of Health
    PI:El Naqa, I.
  • Pyridine Nucleotides: Missing Link between Aging and Lung Cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:DeNicola, G.,CO-PI:Gomes, A.
  • Elucidating PTEN tumor suppression in melanoma
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Karreth, F.
  • Sensitizing Melanoma to Immunotherapy
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Tsai, K.
  • Biophysical basis for enzyme mediated deglycation in protein repair
    Sponsor: Nat Institutes of Health
    PI:Binning, J.
  • Developing mathematical model driven optimized recurrent glioblastoma therapies
    Sponsor: Nat Institutes of Health
    PI (Contact):Enderling, H.,PI:Sahebjam, S.
  • Development of a splicing-based theragnostic biomarker for sensitivity to PRMT5 inhibitors
    Sponsor: Janssen Research Fdtn
    PI:Robinson, T.
  • ODC A allele and aggressive prostate cancer in African American men
    Sponsor: Moffitt Cancer Center
    PI:Rounbehler, R.
  • Mitochondrial DNA diversity: Missing link between African Americans and Lung Cancer disparity
    Sponsor: Moffitt Cancer Center
    PI:Gomes, A.,CO-PI:DeNicola, G.
  • Biological Determinants of Colorectal Cancer Outcomes in Latinos of Diverse Ancestral Origins
    Sponsor: Nat Institutes of Health
    PI:Teer, J.
  • Defining and targeting the pro-tumorigenic metabolic microenvironment of leptomeningeal metastasis in triple-negative breast cancer
    Sponsor: Florida Breast Cancer Foundation
    PI (Contact):Smalley, I.
  • Evolving, understanding and optimising novel Cancer therapies
    Sponsor: US Dept of Energy
    PI:Anderson, A.
  • NADK as an essential metabolic adaptation of metastatic triple negative breast cancer
    Sponsor: Florida Breast Cancer Foundation
    PI:Gomes, A.
  • A dual epigenetic/autophagy inhibitor as a novel strategy to treat triple negative breast cancer
    Sponsor: Florida Breast Cancer Foundation
    PI:Tauro, M.
  • Objective Evaluation of Machine Learning Potential for Automated Segmentation and Generation of Head and Neck Plans with Proven Reduced Toxicity
    Sponsor: Varian Medical Systems, Inc.
    PI:Feygelman, V.,CO-PI:Caudell, J.,CO-PI:Latifi, K.,CO-PI:Moros, E.
  • Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2
    Sponsor: Nat Institutes of Health
    PI:Kissil, J.
  • Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets
    Sponsor: Nat Institutes of Health
    PI:Kissil, J.
Publications
  • Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer. 2021 Jul.127(13):2251-2261. Pubmedid: 33826754.
  • Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, Mo Q, Shao H, Zhang L, Sokol L. Large granular lymphocytic leukemia - A retrospective study of 319 cases. Am J Hematol. 2021 Jul.96(7):772-780. Pubmedid: 33819354.
  • Parikh N, Keshishian E, Manley B, Grass GD, Torres-Roca J, Boulware D, Feuerlein S, Pow-Sang JM, Bagla S, Yamoah K, Bhatia S. Effectiveness and Safety of Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms from Benign Prostatic Hyperplasia in Men with Concurrent Localized Prostate Cancer. J Vasc Interv Radiol. 2021 Jul.32(7):1053-1061. Pubmedid: 33794373.
  • González-Sánchez P, DeNicola GM. The microbiome(s) and cancer: know thy neighbor(s). J Pathol. 2021 Jul.254(4):332-343. Pubmedid: 33723873.
  • Hajiran A, Azizi M, Aydin AM, Chakiryan NH, Peyton CC, Boulware DC, Manley BJ, Gilbert SM, Sexton WJ. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Ann Surg Oncol. 2021 Jul.28(7):3648-3655. Pubmedid: 33689081.
  • Cui S, Ten Haken RK, El Naqa I. Integrating Multiomics Information in Deep Learning Architectures for Joint Actuarial Outcome Prediction in Non-Small Cell Lung Cancer Patients After Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021 Jul.110(3):893-904. Pubmedid: 33539966. Pmcid: PMC8180510.
  • Meyer JM, Lee E, Celli A, Park K, Cho R, Lambert W, Pitchford M, Gordon M, Tsai K, Cleaver J, Arron ST, Mauro TM. CERKL is upregulated in cutaneous squamous cell carcinoma and maintains cellular sphingolipids and resistance to oxidative stress. Br J Dermatol. 2021 Jul.185(1):147-152. Pubmedid: 33393080.
  • Niell BL, Abdalah M, Stringfield O, Raghunand N, Ataya D, Gillies R, Balagurunathan Y. Quantitative Measures of Background Parenchymal Enhancement Predict Breast Cancer Risk. Ajr Am J Roentgenol. 2021 Jul.217(1):64-75. Pubmedid: 32876474.
  • Karreth FA, Ala U, Provero P, Pandolfi PP. Pseudogenes as Competitive Endogenous RNAs: Target Prediction and Validation. Methods Mol Biol. 2021 Jun.2324:115-129. Pubmedid: 34165712.
  • Xu X, Karreth FA. Pseudogenes as Competitive Endogenous RNAs: Testing miRNA Dependency. Methods Mol Biol. 2021 Jun.2324:131-147. Pubmedid: 34165713.
  • Bok I, Karreth FA. Strategies to Study the Functions of Pseudogenes in Mouse Models of Cancer. Methods Mol Biol. 2021 Jun.2324:287-304. Pubmedid: 34165722.
  • Schild T, McReynolds MR, Shea C, Low V, Schaffer BE, Asara JM, Piskounova E, Dephoure N, Rabinowitz JD, Gomes AP, Blenis J. NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma. Cell Rep. 2021 Jun.35(11):109238. Pubmedid: 34133937.
  • Mu W, Jiang L, Shi Y, Tunali I, Gray JE, Katsoulakis E, Tian J, Gillies RJ, Schabath MB. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. J Immunother Cancer. 2021 Jun.9(6). Pubmedid: 34135101. Pmcid: PMC8211060.
  • Jinesh GG, Napoli M, Smallin MT, Davis A, Ackerman HD, Raulji P, Montey N, Flores ER, Brohl AS. Mutant p53s and chromosome 19 microRNA cluster overexpression regulate cancer testis antigen expression and cellular transformation in hepatocellular carcinoma. Sci Rep. 2021 Jun.11(1):12673. Pubmedid: 34135394. Pmcid: PMC8209049.
  • Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 Jun.e29188. Pubmedid: 34137164.
  • Wright GM, Gimbrone NT, Sarcar B, Percy TR, Gordián ER, Kinose F, Sumi NJ, Rix U, Cress WD. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. PLoS One. 2021 Jun.16(6):e0252927. Pubmedid: 34138895. Pmcid: PMC8211232.
  • Felder SI, Fleming JB, Gatenby RA. Treatment-induced evolutionary dynamics in nonmetastatic locally advanced rectal adenocarcinoma. Adv Cancer Res. 2021 Jun.151:39-67. Pubmedid: 34148619.
  • Subramanian S, Han G, Olson N, Leong SP, Kashani-Sabet M, White RL, Zager JS, Sondak VK, Messina JL, Pockaj B, Kosiorek HE, Vetto J, Fowler G, Schneebaum S, Han D. Regression is significantly associated with outcomes for patients with melanoma. Surgery. 2021 Jun. Pubmedid: 34120749.
  • DeNicola GM, Shackelford DB. Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer. Cold Spring Harb Perspect Med. 2021 Jun. Pubmedid: 34127512.
  • Krishnan V, Peng K, Sarode A, Prakash S, Zhao Z, Filippov SK, Todorova K, Sell BR, Lujano O, Bakre S, Pusuluri A, Vogus D, Tsai KY, Mandinova A, Mitragotri S. Hyaluronic acid conjugates for topical treatment of skin cancer lesions. Sci Adv. 2021 Jun.7(24). Pubmedid: 34117055. Pmcid: PMC8195472.
  • Ackerman RS, Luddy KA, Icard BE, Piñeiro Fernández J, Gatenby RA, Muncey AR. The Effects of Anesthetics and Perioperative Medications on Immune Function: A Narrative Review. Anesth Analg. 2021 Jun. Pubmedid: 34100781.
  • Zahid MU, Mohsin N, Mohamed ASR, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Forecasting Individual Patient Response to Radiotherapy in Head and Neck Cancer with a Dynamic Carrying Capacity Model. Int J Radiat Oncol Biol Phys. 2021 Jun. Pubmedid: 34102299.
  • Liu J, Hormuth DA, Davis T, Yang J, McKenna MT, Jarrett AM, Enderling H, Brock A, Yankeelov TE. A time-resolved experimental-mathematical model for predicting the response of glioma cells to single-dose radiation therapy. Integr Biol (Camb). 2021 Jun. Pubmedid: 34060613.
  • Ho JS, Di Tullio F, Schwarz M, Low D, Incarnato D, Gay F, Tabaglio T, Zhang J, Wollmann H, Chen L, An O, Chan THM, Hall Hickman A, Zheng S, Roudko V, Chen S, Karz A, Ahmed M, He HH, Greenbaum BD, Oliviero S, Serresi M, Gargiulo G, Mann KM, Hernando E, Mulholland D, Marazzi I, Wee DKB, Guccione E. HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness. Elife. 2021 Jun.10. Pubmedid: 34075878.
  • Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, Hampton OA, Tungesvik A, De Avila G, Alugubelli RR, Nishihori T, Silva AS, Eschrich SA, Garrett TJ, Koomen JM, Shain KH. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. J Proteome Res. 2021 Jun.20(6):3134-3149. Pubmedid: 34014671.
  • Geiger JL, Ismaila N, Beadle B, Caudell JJ, Chau N, Deschler D, Glastonbury C, Kaufman M, Lamarre E, Lau HY, Licitra L, Moore MG, Rodriguez C, Roshal A, Seethala R, Swiecicki P, Ha P. Management of Salivary Gland Malignancy: ASCO Guideline. J Clin Oncol. 2021 Jun.39(17):1909-1941. Pubmedid: 33900808.
  • Messan MR, Damaghi M, Freischel A, Miao Y, Brown J, Gillies R, Wallace D. Predicting the results of competition between two breast cancer lines grown in 3-D spheroid culture. Math Biosci. 2021 Jun.336:108575. Pubmedid: 33757835.
  • Vargo JA, Moiseenko V, Grimm J, Caudell J, Clump DA, Yorke E, Xue J, Vinogradskiy Y, Moros EG, Mavroidis P, Jain S, El Naqa I, Marks LB, Heron DE. Head and Neck Tumor Control Probability: Radiation Dose-Volume Effects in Stereotactic Body Radiation Therapy for Locally Recurrent Previously-Irradiated Head and Neck Cancer: Report of the AAPM Working Group. Int J Radiat Oncol Biol Phys. 2021 May.110(1):137-146. Pubmedid: 29477291. Pmcid: PMC7294512.
  • Boyle TA, Mondal AK, Saeed-Vafa D, Ananth S, Ahluwalia P, Kothapalli R, Chaubey A, Roberts E, Qin D, Magliocco AM, Rojiani AM, Kolhe R. Guideline-Adherent Clinical Validation of a Comprehensive 170-Gene DNA/RNA Panel for Determination of Small Variants, Copy Number Variations, Splice Variants, and Fusions on a Next-Generation Sequencing Platform in the CLIA Setting. Front Genet. 2021 May.12:503830. Pubmedid: 34093633. Pmcid: PMC8172991.
  • Hicks JK, Howard R, Reisman P, Adashek JJ, Fields KK, Gray JE, McIver B, McKee K, O'Leary MF, Perkins RM, Robinson E, Tandon A, Teer JK, Markowitz J, Rollison DE. Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. JCO Precis Oncol. 2021 May.5. Pubmedid: 34095711. Pmcid: PMC8169076.
  • Ordway B, Gillies RJ, Damaghi M. Extracellular Acidification Induces Lysosomal Dysregulation. Cells. 2021 May.10(5). Pubmedid: 34067971. Pmcid: PMC8152284.
  • Nakanishi S, Cleveland JL. Polyamine Homeostasis in Development and Disease. Med Sci (Basel). 2021 May.9(2). Pubmedid: 34068137. Pmcid: PMC8162569.
  • Hope A, Verduin M, Dilling TJ, Choudhury A, Fijten R, Wee L, Aerts HJ, El Naqa I, Mitchell R, Vooijs M, Dekker A, de Ruysscher D, Traverso A. Artificial Intelligence Applications to Improve the Treatment of Locally Advanced Non-Small Cell Lung Cancers. Cancers (Basel). 2021 May.13(10). Pubmedid: 34069307. Pmcid: PMC8156328.
  • Hasipek M, Grabowski D, Guan Y, Alugubelli RR, Tiwari AD, Gu X, DeAvila GA, Silva AS, Meads MB, Parker Y, Lindner DJ, Saunthararajah Y, Shain KH, Maciejewski JP, Reu FJ, Phillips JG, Jha BK. Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. Cancers (Basel). 2021 May.13(11). Pubmedid: 34071205. Pmcid: PMC8198550.
  • Smalley I, Chen Z, Phadke MS, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clin Cancer Res. 2021 May. Pubmedid: 34035069.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathologic Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 May. Pubmedid: 34032503.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2021 May.4(5):e2111329. Pubmedid: 34032854. Pmcid: PMC8150693.
  • Moiseenko V, Hattangadi-Gluth JA, Huynh-Le MP, Marks LB, Grimm J, Milano MT, Jackson A, Yorke E, Pettersson N, Naqa IE. In Reply to Schultheiss. Int J Radiat Oncol Biol Phys. 2021 May. Pubmedid: 34024669.
  • Mills MN, Naz A, Thawani C, Walker C, Figura NB, Kushchayev S, Oliver DE, Etame AB, Yu HM, Robinson TJ, Liu JKC, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases. BMC Cancer. 2021 May.21(1):552. Pubmedid: 33992087. Pmcid: PMC8126143.
  • Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2021 May. Pubmedid: 33994165.
  • Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
  • Gillies RJ. Cancer heterogeneity and metastasis: life at the edge. Clin Exp Metastas. 2021 May. Pubmedid: 33999364.
  • Eschrich SA, Teer JK, Reisman P, Siegel E, Challa C, Lewis P, Fellows K, Malpica E, Carvajal R, Gonzalez G, Cukras S, Betin-Montes M, Aden-Buie G, Avedon M, Manning D, Tan AC, Fridley BL, Gerke T, Van Looveren M, Blake A, Greenman J, Rollison D. Enabling Precision Medicine in Cancer Care Through a Molecular Data Warehouse: The Moffitt Experience. JCO Clin Cancer Inform. 2021 May.5:561-569. Pubmedid: 33989014.
  • McLeod KL, Skinner AM, Beaupin LK, Vadaparampil ST, Fridley BL, Reed DR. Clinical Trial Availability by Location for 1000 Simulated AYA Patients. J Adolesc Young Adult Oncol. 2021 May. Pubmedid: 33983850.
  • Smalley KSM, Teer JK, Chen YA, Wu JY, Yao J, Koomen JM, Chen WS, Rodriguez-Waitkus P, Karreth FA, Messina JL. A Mutational Survey of Acral Nevi. JAMA Dermatol. 2021 May. Pubmedid: 33978681. Pmcid: PMC8117064.
  • Pasetto S, Gatenby RA, Enderling H. Bayesian Framework to Augment Tumor Board Decision Making. JCO Clin Cancer Inform. 2021 May.5:508-517. Pubmedid: 33974446.
  • Alix-Panabieres C, Magliocco A, Cortes-Hernandez LE, Eslami-S Z, Franklin D, Messina JL. Detection of cancer metastasis: past, present and future. Clin Exp Metastas. 2021 May. Pubmedid: 33961169.
  • Egan KM, Kim Y, Bender N, Hodge JM, Coghill AE, Smith-Warner SA, Rollison DE, Teras LR, Grimsrud TK, Waterboer T. Prospective investigation of polyomavirus infection and the risk of adult glioma. Sci Rep. 2021 May.11(1):9642. Pubmedid: 33953301. Pmcid: PMC8100283.
  • Siegel EL, Whiting J, Kim Y, Sun W, Laronga C, Lee MC. Effect of surgical complications on outcomes in breast cancer patients treated with mastectomy and immediate reconstruction. Breast Cancer Res Treat. 2021 May. Pubmedid: 33939063.
  • Tomaszewski MR, Gillies RJ. The Biological Meaning of Radiomic Features. Radiology. 2021 May.299(2):E256. Pubmedid: 33900879.
  • Stumpf PK, Yorke ED, El Naqa I, Cuneo KC, Grimm J, Goodman KA. Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors. Int J Radiat Oncol Biol Phys. 2021 May.110(1):217-226. Pubmedid: 33864824.
  • Owen DR, Sun Y, Boonstra PS, McFarlane M, Viglianti BL, Balter JM, El Naqa I, Schipper MJ, Schonewolf CA, Ten Haken RK, Kong FS, Jolly S, Matuszak MM. Investigating the SPECT Dose-Function Metrics Associated With Radiation-Induced Lung Toxicity Risk in Patients With Non-small Cell Lung Cancer Undergoing Radiation Therapy. Adv Radiat Oncol. 2021 May.6(3):100666. Pubmedid: 33817412. Pmcid: PMC8010578.
  • Coates JTT, Pirovano G, El Naqa I. Radiomic and radiogenomic modeling for radiotherapy: strategies, pitfalls, and challenges. J Med Imaging (Bellingham). 2021 May.8(3):031902. Pubmedid: 33768134. Pmcid: PMC7985651.
  • Mills MN, Thawani C, Figura NB, Oliver DE, Soyano AE, Etame A, Robinson TJ, Liu JK, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Yu HM, Ahmed KA. Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. J Neurooncol. 2021 May.152(3):591-601. Pubmedid: 33742358.
  • Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett D, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM. Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunol Res. 2021 May.9(5):554-567. Pubmedid: 33653716. Pmcid: PMC8102376.
  • Grimm J, Vargo JA, Mavroidis P, Moiseenko V, Emami B, Jain S, Caudell JJ, Clump DA, Ling DC, Das S, Moros EG, Vinogradskiy Y, Xue J, Heron DE. Initial Data Pooling for Radiation Dose-Volume Tolerance for Carotid Artery Blowout and Other Bleeding Events in Hypofractionated Head and Neck Retreatments. Int J Radiat Oncol Biol Phys. 2021 May.110(1):147-159. Pubmedid: 33583641.
  • Vogelbaum MA, Kroll D, Etame A, Tran N, Liu J, Ford A, Sparr E, Kim Y, Forsyth P, Sahebjam S, Mokhtari S, Peguero E, Macaulay R. A Prospective Validation Study of the First 3D Digital Exoscope for Visualization of 5-ALA-Induced Fluorescence in High-Grade Gliomas. World Neurosurg. 2021 May.149:e498-e503. Pubmedid: 33561551.
  • Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Chi P, Burd CE, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G. Melanoma models for the next generation of therapies. Cancer Cell. 2021 May.39(5):610-631. Pubmedid: 33545064.
  • Lo CH, Shay G, McGuire J, Li T, Shain K, Choi JY, Fuerst R, Roush WR, Knapinska AM, Fields GB, Lynch CC. Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival. Cancer Res. 2021 May.81(9):2415-2428. Pubmedid: 33526510.
  • Soltys SG, Grimm J, Milano MT, Xue J, Sahgal A, Yorke E, Yamada Y, Ding GX, Li XA, Lovelock DM, Jackson A, Ma L, El Naqa I, Gibbs IC, Marks LB, Benedict S. Stereotactic Body Radiation Therapy for Spinal Metastases: Tumor Control Probability Analyses and Recommended Reporting Standards. Int J Radiat Oncol Biol Phys. 2021 May.110(1):112-123. Pubmedid: 33516580.
  • Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021 May.39(14):1584-1594. Pubmedid: 33449813. Pmcid: PMC8099410.
  • Redmond KJ, Gui C, Benedict S, Milano MT, Grimm J, Vargo JA, Soltys SG, Yorke E, Jackson A, El Naqa I, Marks LB, Xue J, Heron DE, Kleinberg LR. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys. 2021 May.110(1):53-67. Pubmedid: 33390244.
  • Soltys SG, Milano MT, Xue J, Tomé WA, Yorke E, Sheehan J, Ding GX, Kirkpatrick JP, Ma L, Sahgal A, Solberg T, Adler J, Grimm J, El Naqa I. Stereotactic Radiosurgery for Vestibular Schwannomas: Tumor Control Probability Analyses and Recommended Reporting Standards. Int J Radiat Oncol Biol Phys. 2021 May.110(1):100-111. Pubmedid: 33375955.
  • Wang K, Mavroidis P, Royce TJ, Falchook AD, Collins SP, Sapareto S, Sheets NC, Fuller DB, El Naqa I, Yorke E, Grimm J, Jackson A, Chen RC. Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response. Int J Radiat Oncol Biol Phys. 2021 May.110(1):237-248. Pubmedid: 33358229. Pmcid: PMC8053668.
  • Moiseenko V, Marks LB, Grimm J, Jackson A, Milano MT, Hattangadi-Gluth JA, Huynh-Le MP, Pettersson N, Yorke E, El Naqa I. A Primer on Dose-Response Data Modeling in Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021 May.110(1):11-20. Pubmedid: 33358230.
  • Safa H, Tamil M, Spiess PE, Manley B, Pow-Sang J, Gilbert S, Safa F, Gonzalez BD, Oswald LB, Semaan A, Diab A, Chahoud J. Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. J Natl Cancer Inst. 2021 May.113(5):532-542. Pubmedid: 33146385. Pmcid: PMC8096374.
  • Royce TJ, Mavroidis P, Wang K, Falchook AD, Sheets NC, Fuller DB, Collins SP, El Naqa I, Song DY, Ding GX, Nahum AE, Jackson A, Grimm J, Yorke E, Chen RC. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 May.110(1):227-236. Pubmedid: 32900561.
  • Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
  • Milano MT, Grimm J, Soltys SG, Yorke E, Moiseenko V, Tomé WA, Sahgal A, Xue J, Ma L, Solberg TD, Kirkpatrick JP, Constine LS, Flickinger JC, Marks LB, El Naqa I. Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways. Int J Radiat Oncol Biol Phys. 2021 May.110(1):87-99. Pubmedid: 29534899.
  • Marciscano AE, Haimovitz-Friedman A, Lee P, Tran PT, Tomé WA, Guha C, Spring Kong FM, Sahgal A, El Naqa I, Rimner A, Marks LB, Formenti SC, DeWeese TL. Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. Int J Radiat Oncol Biol Phys. 2021 May.110(1):35-52. Pubmedid: 30836168.
  • Lee P, Loo BW, Biswas T, Ding GX, El Naqa IM, Jackson A, Kong FM, LaCouture T, Miften M, Solberg T, Tome WA, Tai A, Yorke E, Li XA. Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 May.110(1):160-171. Pubmedid: 30954520.
  • Jain RK, Skelton Iv WP, Pond GR, Naqvi M, Kim Y, Curran C, Freeman D, Nuzzo PV, Alaiwi SA, Nassar AH, Jain RK, Sonpavde G. Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2021 Apr. Pubmedid: 34011489.
  • Azimzade Y, Saberi AA, Gatenby RA. Superlinear growth reveals the Allee effect in tumors. Phys Rev E. 2021 Apr.103(4-1):042405. Pubmedid: 34005934.
  • Sauer S, Reed DR, Ihnat M, Hurst RE, Warshawsky D, Barkan D. Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells. Front Oncol. 2021 Apr.11:659963. Pubmedid: 33987095. Pmcid: PMC8111294.
  • Lin HY, Huang PY, Cheng CH, Tung HY, Fang Z, Berglund AE, Chen A, French-Kwawu J, Harris D, Pow-Sang J, Yamoah K, Cleveland JL, Awasthi S, Rounbehler RJ, Gerke T, Dhillon J, Eeles R, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Neal DE, Nielsen SF, Nordestgaard BG, Gronberg H, Wiklund F, Giles GG, Haiman CA, Travis RC, Stanford JL, Kibel AS, Cybulski C, Khaw KT, Maier C, Thibodeau SN, Teixeira MR, Cannon-Albright L, Brenner H, Kaneva R, Pandha H, Srinivasan S, Clements J, Batra J, Park JY. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci Rep. 2021 Apr.11(1):9264. Pubmedid: 33927218. Pmcid: PMC8084951.
  • Rivera-Rivera Y, Marina M, Jusino S, Lee M, Velázquez JV, Chardón-Colón C, Vargas G, Padmanabhan J, Chellappan SP, Saavedra HI. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells. Sci Rep. 2021 Apr.11(1):9016. Pubmedid: 33907253. Pmcid: PMC8079711.
  • Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 Apr. Pubmedid: 33910263.
  • Dujon AM, Aktipis A, Alix-Panabières C, Amend SR, Boddy AM, Brown JS, Capp JP, DeGregori J, Ewald P, Gatenby R, Gerlinger M, Giraudeau M, Hamede RK, Hansen E, Kareva I, Maley CC, Marusyk A, McGranahan N, Metzger MJ, Nedelcu AM, Noble R, Nunney L, Pienta KJ, Polyak K, Pujol P, Read AF, Roche B, Sebens S, Solary E, Staňková K, Swain Ewald H, Thomas F, Ujvari B. Identifying key questions in the ecology and evolution of cancer. Evol Appl. 2021 Apr.14(4):877-892. Pubmedid: 33897809. Pmcid: PMC8061275.
  • Patel SY, Trona N, Alford B, Laborde JM, Kim Y, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy. Nutr Clin Pract. 2021 Apr. Pubmedid: 33900647.
  • Xie M, Lee K, Lockhart JH, Cukras SD, Carvajal R, Beg AA, Flores ER, Teng M, Chung CH, Tan AC. TIMEx: tumor-immune microenvironment deconvolution web-portal for bulk transcriptomics using pan-cancer scRNA-seq signatures. Bioinformatics. 2021 Apr. Pubmedid: 33901274.
  • Straker RJ, Carr MJ, Sinnamon AJ, Shannon AB, Sun J, Landa K, Baecher KM, Wood C, Lynch K, Bartels HG, Panchaud R, Lowe MC, Slingluff CL, Jameson MJ, Tsai K, Faries MB, Beasley GM, Sondak V, Karakousis GC, Zager JS, Miura JT. Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. Ann Surg Oncol. 2021 Apr. Pubmedid: 33890195.
  • Check DK, Bagett CD, Kim K, Roberts AW, Roberts MC, Robinson T, Oeffinger KC, Dinan MA. Predictors of Chronic Opioid Use: A Population-level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims. J Natl Cancer Inst. 2021 Apr. Pubmedid: 33881543.
  • Chakiryan NH, Kimmel GJ, Kim Y, Hajiran A, Aydin AM, Zemp L, Katende E, Nguyen J, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, El-Kenawi A, Mulé J, Altrock PM, Manley BJ. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PLoS One. 2021 Apr.16(4):e0245415. Pubmedid: 33882057. Pmcid: PMC8059840.
  • Vaught DB, Merkel AR, Lynch CC, Edwards J, Tantawy MN, Hilliard T, Wang S, Peterson T, Johnson RW, Sterling JA, Brantley-Sieders D. EphA2 Is a Clinically Relevant Target for Breast Cancer Bone Metastatic Disease. JBMR Plus. 2021 Apr.5(4):e10465. Pubmedid: 33869989. Pmcid: PMC8046157.
  • McGee KP, Hwang K, Sullivan DC, Kurhanewicz J, Hu Y, Wang J, Li W, Debbins J, Paulson E, Olsen JR, Hua CH, Warner L, Ma D, Moros E, Tyagi N, Chung C. Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294. Med Phys. 2021 Apr. Pubmedid: 33864283.
  • Tafreshi NK, Kil H, Pandya DN, Tichacek CJ, Doligalski ML, Budzevich MM, Delva NC, Langsen ML, Vallas JA, Boulware DC, Engelman RW, Gage KL, Moros EG, Wadas TJ, McLaughlin ML, Morse DL. Lipophilicity Determines Routes of Uptake and Clearance, and Toxicity of an Alpha-Particle-Emitting Peptide Receptor Radiotherapy. ACS Pharmacol Transl Sci. 2021 Apr.4(2):953-965. Pubmedid: 33860213. Pmcid: PMC8033749.
  • West J, Schenck RO, Gatenbee C, Robertson-Tessi M, Anderson ARA. Normal tissue architecture determines the evolutionary course of cancer. Nat Commun. 2021 Apr.12(1):2060. Pubmedid: 33824323. Pmcid: PMC8024392.
  • Mu W, Katsoulakis E, Whelan CJ, Gage KL, Schabath MB, Gillies RJ. Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors. Brit J Cancer. 2021 Apr. Pubmedid: 33828255.
  • Zaidi H, El Naqa I. Quantitative Molecular Positron Emission Tomography Imaging Using Advanced Deep Learning Techniques. Annu Rev Biomed Eng. 2021 Apr. Pubmedid: 33797938.
  • Liu HY, Tam L, Woody NM, Caudell J, Reddy CA, Ghanem A, Schymick M, Joshi N, Geiger J, Lamarre E, Burkey B, Adelstein D, Dunlap N, Siddiqui F, Koyfman S, Porceddu SV. Failure rate in the untreated contralateral node negative neck of small lateralized oral cavity cancers: A multi-institutional collaborative study. Oral Oncol. 2021 Apr.115:105190. Pubmedid: 33581503.
  • Cote DJ, Smith-Warner SA, Creed JH, Furtado J, Gerke T, Wang M, Kim Y, Stampfer MJ, Egan KM. Circulating lipids and glioma risk: results from the UK Biobank, Nurses' Health Study, and Health Professionals Follow-Up Study. Cancer Causes Control. 2021 Apr.32(4):347-355. Pubmedid: 33484419.
  • Jia Y, Kodumudi KN, Ramamoorthi G, Basu A, Snyder C, Wiener D, Pilon-Thomas S, Grover P, Zhang H, Greene MI, Mo Q, Tong Z, Chen YZ, Costa RLB, Han H, Lee C, Soliman H, Conejo-Garcia JR, Koski G, Czerniecki BJ. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Mol Ther. 2021 Apr.29(4):1541-1556. Pubmedid: 33412308. Pmcid: PMC8058490.
  • Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 Apr.204(1):96-106. Pubmedid: 33346915. Pmcid: PMC7944355.
  • Persi E, Wolf YI, Horn D, Ruppin E, Demichelis F, Gatenby RA, Gillies RJ, Koonin EV. Publisher Correction: Mutation-selection balance and compensatory mechanisms in tumour evolution. Nat Rev Genet. 2021 Apr.22(4):263. Pubmedid: 33318707.
  • Persi E, Wolf YI, Horn D, Ruppin E, Demichelis F, Gatenby RA, Gillies RJ, Koonin EV. Mutation-selection balance and compensatory mechanisms in tumour evolution. Nat Rev Genet. 2021 Apr.22(4):251-262. Pubmedid: 33257848.
  • Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neurooncol. 2021 Apr.23(4):677-686. Pubmedid: 33173935. Pmcid: PMC8041351.
  • Zhang C, Smalley I, Emmons MF, Sharma R, Izumi V, Messina J, Koomen JM, Pasquale EB, Forsyth PA, Smalley KSM. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma. J Invest Dermatol. 2021 Apr.141(4):840-851.e4. Pubmedid: 32890629. Pmcid: PMC7921215.
  • Daou H, Hatch LA, Weinkle A, Morey GE, Messina J, Zhang X, Sokol L, Seminario-Vidal L. CD8-positive cutaneous lymphoproliferation associated with large granular lymphocyte leukemia in a patient with X-linked agammaglobulinemia. J Cutan Pathol. 2021 Apr.48(4):567-571. Pubmedid: 32885480.
  • Zaman S, Hajiran A, Coba GA, Robinson T, Madanayake TW, Segarra DT, Chobrutskiy BI, Boyle TA, Zhou JM, Kim Y, Mulé JJ, Teer JK, Manley BJ. Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. Eur Urol Focus. 2021 Mar.7(2):373-380. Pubmedid: 31901438. Pmcid: PMC7771328.
  • Jardim-Perassi BV, Mu W, Huang S, Tomaszewski MR, Poleszczuk J, Abdalah MA, Budzevich MM, Dominguez-Viqueira W, Reed DR, Bui MM, Johnson JO, Martinez GV, Gillies RJ. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma. Theranostics. 2021 Mar.11(11):5313-5329. Pubmedid: 33859749. Pmcid: PMC8039958.
  • Yun S, Vincelette ND, Yu X, Watson GW, Fernandez MR, Yang C, Hitosugi T, Cheng CH, Freischel AR, Zhang L, Li W, Hou H, Schaub FX, Vedder AR, Cen L, McGraw KL, Moon J, Murphy DJ, Ballabio A, Kaufmann SH, Berglund AE, Cleveland JL. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discov. 2021 Mar.2(2):162-185. Pubmedid: 33860275. Pmcid: PMC8043621.
  • Mason NT, Burkett JM, Nelson RS, Pow-Sang JM, Gatenby RA, Kubal T, Peabody JW, Letson GD, McLeod HL, Zhang J. Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer. Am Health Drug Benefits. 2021 Mar.14(1):15-20. Pubmedid: 33841621. Pmcid: PMC8025923.
  • Vera O, Bok I, Jasani N, Nakamura K, Xu X, Mecozzi N, Angarita A, Wang K, Tsai KY, Karreth FA. A MAPK/miR-29 Axis Suppresses Melanoma by Targeting MAFG and MYBL2. Cancers (Basel). 2021 Mar.13(6). Pubmedid: 33808771. Pmcid: PMC8003541.
  • Mahajan A, Stavinoha PL, Rongthong W, Brodin NP, McGovern SL, El Naqa I, Palmer JD, Vennarini S, Indelicato DJ, Aridgides P, Bowers DC, Kremer L, Ronckers C, Constine L, Avanzo M. Neurocognitive Effects and Necrosis in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys. 2021 Mar. Pubmedid: 33810950.
  • Capp JP, DeGregori J, Nedelcu AM, Dujon AM, Boutry J, Pujol P, Alix-Panabières C, Hamede R, Roche B, Ujvari B, Marusyk A, Gatenby R, Thomas F. Group phenotypic composition in cancer. Elife. 2021 Mar.10. Pubmedid: 33784238. Pmcid: PMC8009660.
  • Kamal Y, Dwan D, Hoehn HJ, Sanz-Pamplona R, Alonso MH, Moreno V, Cheng C, Schell MJ, Kim Y, Felder SI, Rennert HS, Melas M, Lazaris C, Bonner JD, Siegel EM, Shibata D, Rennert G, Gruber SB, Frost HR, Amos CI, Schmit SL. Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse. Oncoimmunology. 2021 Mar.10(1):1862529. Pubmedid: 33763292. Pmcid: PMC7951964.
  • Lo CH, Baratchart E, Basanta D, Lynch CC. Computational modeling reveals a key role for polarized myeloid cells in controlling osteoclast activity during bone injury repair. Sci Rep. 2021 Mar.11(1):6055. Pubmedid: 33723343. Pmcid: PMC7961065.
  • Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, Meads MB, Ren Y, Li T, Sun J, Fahmi NA, Singh S, Sehgal L, Wang X, Silva AS, Sotomayor EM, Shain KH, Cleveland JL, Wang M, Zhang W, Qi J, Shah BD, Tao J. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep. 2021 Mar.34(11):108870. Pubmedid: 33730585. Pmcid: PMC8057695.
  • Balagurunathan Y, Mitchell R, El Naqa I. Requirements and reliability of AI in the medical context. Phys Med. 2021 Mar.83:72-78. Pubmedid: 33721700.
  • Artzy-Randrup Y, Epstein T, Brown JS, Costa RLB, Czerniecki BJ, Gatenby RA. Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy. NPJ Breast Cancer. 2021 Mar.7(1):26. Pubmedid: 33707440. Pmcid: PMC7952601.
  • Pressley M, Gallaher JA, Brown JS, Tomaszewski MR, Borad P, Damaghi M, Gillies RJ, Whelan CJ. Cycling hypoxia selects for constitutive HIF stabilization. Sci Rep. 2021 Mar.11(1):5777. Pubmedid: 33707510. Pmcid: PMC7952589.
  • Grove O, Berglund AE, Schabath MB, Aerts HJWL, Dekker A, Wang H, Velazquez ER, Lambin P, Gu Y, Balagurunathan Y, Eikman E, Gatenby RA, Eschrich S, Gillies RJ. Correction: Quantitative Computed Tomographic Descriptors Associate Tumor Shape Complexity and Intratumor Heterogeneity with Prognosis in Lung Adenocarcinoma. PLoS One. 2021 Mar.16(3):e0248541. Pubmedid: 33684181. Pmcid: PMC7939347.
  • Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, Etame A, Yu HM, Robinson TJ, Liu J, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021 Mar.21(1):223. Pubmedid: 33663447. Pmcid: PMC7934378.
  • Ward NP, DeNicola GM. GSH hoards all the cysteine-what a slimy thing to do. Nat Metab. 2021 Mar.3(3):297-298. Pubmedid: 33664498.
  • Freischel AR, Damaghi M, Cunningham JJ, Ibrahim-Hashim A, Gillies RJ, Gatenby RA, Brown JS. Frequency-dependent interactions determine outcome of competition between two breast cancer cell lines. Sci Rep. 2021 Mar.11(1):4908. Pubmedid: 33649456. Pmcid: PMC7921689.
  • Wu HH, Wang B, Armstrong SR, Abuetabh Y, Leng S, Roa WHY, Atfi A, Marchese A, Wilson B, Sergi C, Flores ER, Eisenstat DD, Leng RP. Hsp70 acts as a fine-switch that controls E3 ligase CHIP-mediated TAp63 and ΔNp63 ubiquitination and degradation. Nucleic Acids Res. 2021 Mar.49(5):2740-2758. Pubmedid: 33619536. Pmcid: PMC7969027.
  • Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, Mine JA, Trillo-Tinoco J, Sasamoto N, Terry KL, Marchion D, Buras A, Wenham RM, Yu X, Townsend MK, Tworoger SS, Rodriguez PC, Anderson AR, Conejo-Garcia JR. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021 Mar.591(7850):464-470. Pubmedid: 33536615. Pmcid: PMC7969354.
  • Wei L, El Naqa I. Artificial Intelligence for Response Evaluation With PET/CT. Semin Nucl Med. 2021 Mar.51(2):157-169. Pubmedid: 33509372. Pmcid: PMC8099153.
  • Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, Truong MT, Kong C, Jordan R, Subramaniam RM, Yao M, Chung CH, Geiger JL, Chan JW, O'Sullivan B, Blakaj DM, Mell LK, Thorstad WL, Jones CU, Banerjee RN, Lominska C, Le QT. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). J Clin Oncol. 2021 Mar.39(9):956-965. Pubmedid: 33507809. Pmcid: PMC8078254.
  • Miroshnychenko D, Baratchart E, Ferrall-Fairbanks MC, Velde RV, Laurie MA, Bui MM, Tan AC, Altrock PM, Basanta D, Marusyk A. Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations. Nat Ecol Evol. 2021 Mar.5(3):379-391. Pubmedid: 33462489.
  • Tomaszewski MR, Gillies RJ. The Biological Meaning of Radiomic Features. Radiology. 2021 Mar.298(3):505-516. Pubmedid: 33399513. Pmcid: PMC7924519.
  • Ba Sunbul N, Oraiqat I, Rosen B, Miller C, Meert C, Matuszak MM, Clarke S, Pozzi S, Moran JM, El Naqa I. Application of radiochromic gel dosimetry to commissioning of a megavoltage research linear accelerator for small-field animal irradiation studies. Med Phys. 2021 Mar.48(3):1404-1416. Pubmedid: 33378092.
  • Tomaszewski MR, Dominguez-Viqueira W, Ortiz A, Shi Y, Costello JR, Enderling H, Rosenberg SA, Gillies RJ. Heterogeneity analysis of MRI T2 maps for measurement of early tumor response to radiotherapy. Nmr Biomed. 2021 Mar.34(3):e4454. Pubmedid: 33325086.
  • Divgi C, Carrasquillo JA, Meredith R, Seo Y, Frey EC, Bolch WE, Zimmerman BE, Akabani G, Jacobson DA, Brown B, Davern SM, Hobbs RF, Humm J, Moros EG, Morse D, Papineni R, Zanzonico P, Benedict SH, Sgouros G. Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. Int J Radiat Oncol Biol Phys. 2021 Mar.109(4):905-912. Pubmedid: 33309909.
  • Maan M, Agrawal NJ, Padmanabhan J, Leitzinger CC, Rivera-Rivera Y, Saavedra HI, Chellappan SP. Tank Binding Kinase 1 modulates spindle assembly checkpoint components to regulate mitosis in breast and lung cancer cells. Biochim Biophys Acta Mol Cell Res. 2021 Mar.1868(3):118929. Pubmedid: 33310066. Pmcid: PMC8054712.
  • Scott JG, Sedor G, Scarborough JA, Kattan MW, Peacock J, Grass GD, Mellon EA, Thapa R, Schell M, Waller A, Poppen S, Andl G, Teer J, Eschrich SA, Dilling TJ, Dalton WS, Harrison LB, Fox T, Torres-Roca JF. Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC. J Thorac Oncol. 2021 Mar.16(3):428-438. Pubmedid: 33301984.
  • Yuan Z, Fernandez D, Dhillon J, Abraham-Miranda J, Awasthi S, Kim Y, Zhang J, Jain R, Serna A, Pow-Sang JM, Poch M, Li R, Manley B, Fink A, Naghavi A, Torres-Roca JF, Grass GD, Kim S, Latifi K, Hunt D, Johnstone PAS, Yamoah K. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer P D. 2021 Mar.24(1):140-149. Pubmedid: 32651467. Pmcid: PMC7882397.
  • Yuan Z, Frazer M, Rishi A, Latifi K, Tomaszewski MR, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Zhang GG, Frakes JM. Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy. Rep Pract Oncol Radiother. 2021 Feb.26(1):29-34. Pubmedid: 33948299. Pmcid: PMC8086711.
  • Ilter D, Gomes AP. Age-induced metabolic reprogramming underlies cancer progression. Mol Cell Oncol. 2021 Feb.8(2):1876506. Pubmedid: 33860078. Pmcid: PMC8018342.
  • Wei L, Owen D, Rosen B, Guo X, Cuneo K, Lawrence TS, Ten Haken R, El Naqa I. A deep survival interpretable radiomics model of hepatocellular carcinoma patients. Phys Med. 2021 Feb.82:295-305. Pubmedid: 33714190. Pmcid: PMC8035300.
  • Kim E, Brown JS, Eroglu Z, Anderson ARA. Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33669315. Pmcid: PMC7920057.
  • Permuth JB, Dezsi KB, Vyas S, Ali KN, Basinski TL, Utuama OA, Denbo JW, Klapman J, Dam A, Carballido E, Kim DW, Pimiento JM, Powers BD, Otto AK, Choi JW, Chen DT, Teer JK, Beato F, Ward A, Cortizas EM, Whisner SY, Williams IE, Riner AN, Tardif K, Velanovich V, Karachristos A, Douglas WG, Legaspi A, Allan BJ, Meredith K, Molina-Vega MA, Bao P, St Julien J, Huguet KL, Green L, Odedina FT, Kumar NB, Simmons VN, George TJ, Vadaparampil ST, Hodul PJ, Arnoletti JP, Awad ZT, Bose D, Jiang K, Centeno BA, Gwede CK, Malafa M, Judge SM, Judge AR, Jeong D, Bloomston M, Merchant NB, Fleming JB, Trevino JG. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33671939. Pmcid: PMC7919015.
  • Mazin A, Hawkins SH, Stringfield O, Dhillon J, Manley BJ, Jeong DK, Raghunand N. Identification of sarcomatoid differentiation in renal cell carcinoma by machine learning on multiparametric MRI. Sci Rep. 2021 Feb.11(1):3785. Pubmedid: 33589715. Pmcid: PMC7884398.
  • Araujo A, Cook LM, Frieling JS, Tan W, Copland JA, Kohli M, Gupta S, Dhillon J, Pow-Sang J, Lynch CC, Basanta D. Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33567529. Pmcid: PMC7915310.
  • Davis RR, Li B, Yun SY, Chan A, Nareddy P, Gunawan S, Ayaz M, Lawrence HR, Reuther GW, Lawrence NJ, Schönbrunn E. Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. J Med Chem. 2021 Feb.64(4):2228-2241. Pubmedid: 33570945.
  • Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D'Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKay R, McKenney J, Netto G, Penson DF, Pow-Sang JM, Reiter R, Richey S, Roach Iii M, Rosenfeld S, Shabsigh A, Spratt DE, Teply BA, Tward J, Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Ne. 2021 Feb.19(2):134-143. Pubmedid: 33545689.
  • Moore MR, Friesner ID, Rizk EM, Fullerton BT, Mondal M, Trager MH, Mendelson K, Chikeka I, Kurc T, Gupta R, Rohr BR, Robinson EJ, Acs B, Chang R, Kluger H, Taback B, Geskin LJ, Horst B, Gardner K, Niedt G, Celebi JT, Gartrell-Corrado RD, Messina J, Ferringer T, Rimm DL, Saltz J, Wang J, Vanguri R, Saenger YM. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. Sci Rep. 2021 Feb.11(1):2809. Pubmedid: 33531581. Pmcid: PMC7854647.
  • Mulder RL, Font-Gonzalez A, van Dulmen-den Broeder E, Quinn GP, Ginsberg JP, Loeffen EAH, Hudson MM, Burns KC, van Santen HM, Berger C, Diesch T, Dirksen U, Giwercman A, Gracia C, Hunter SE, Kelvin JF, Klosky JL, Laven JSE, Lockart BA, Neggers SJCMM, Peate M, Phillips B, Reed DR, Tinner EME, Byrne J, Veening M, van de Berg M, Verhaak CM, Anazodo A, Rodriguez-Wallberg K, van den Heuvel-Eibrink MM, Asogwa OA, Brownsdon A, Wallace WH, Green DM, Skinner R, Haupt R, Kenney LB, Levine J, van de Wetering MD, Tissing WJE, Paul NW, Kremer LCM, Inthorn J. Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmoniza. Lancet Oncol. 2021 Feb.22(2):e68-e80. Pubmedid: 33539755.
  • McGuire JJ, Frieling JS, Lo CH, Li T, Muhammad A, Lawrence HR, Lawrence NJ, Cook LM, Lynch CC. Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer. Nat Commun. 2021 Feb.12(1):723. Pubmedid: 33526787. Pmcid: PMC7851397.
  • Pienta KJ, Hammarlund EU, Brown JS, Amend SR, Axelrod RM. Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells. Proc Natl Acad Sci U S A. 2021 Feb.118(7). Pubmedid: 33504594. Pmcid: PMC7896294.
  • Saini A, Tichacek C, Johansson W, Redler G, Zhang G, Moros EG, Qayyum M, Feygelman V. Unlocking a closed system: dosimetric commissioning of a ring gantry linear accelerator in a multivendor environment. J Appl Clin Med Phys. 2021 Feb.22(2):21-34. Pubmedid: 33452738. Pmcid: PMC7882119.
  • Horton TM, Hoff FW, van Dijk A, Jenkins GN, Morrison D, Bhatla T, Hogan L, Romanos-Sirakis E, Meyer J, Carroll WL, Qiu Y, Wang T, Mo Q, Kornblau SM. The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. J Proteomics. 2021 Feb.233:104046. Pubmedid: 33212251. Pmcid: PMC7877245.
  • Strobl MAR, West J, Viossat Y, Damaghi M, Robertson-Tessi M, Brown JS, Gatenby RA, Maini PK, Anderson ARA. Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy. Cancer Res. 2021 Feb.81(4):1135-1147. Pubmedid: 33172930.
  • Massey SC, Whitmire P, Doyle TE, Ippolito JE, Mrugala MM, Hu LS, Canoll P, Anderson ARA, Wilson MA, Fitzpatrick SM, McCarthy MM, Rubin JB, Swanson KR. Sex differences in health and disease: A review of biological sex differences relevant to cancer with a spotlight on glioma. Cancer Lett. 2021 Feb.498:178-187. Pubmedid: 33130315.
  • Yamoah K, Lal P, Awasthi S, Naghavi AO, Rounbehler RJ, Gerke T, Berglund AE, Pow-Sang JM, Schaeffer EM, Dhillon J, Park JY, Rebbeck TR. TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer. Prostate. 2021 Feb.81(2):109-117. Pubmedid: 33141952. Pmcid: PMC7810127.
  • Beato F, Reverón D, Dezsi KB, Ortiz A, Johnson JO, Chen DT, Ali K, Yoder SJ, Jeong D, Malafa M, Hodul P, Jiang K, Centeno BA, Abdalah MA, Balasi JA, Tassielli AF, Sarcar B, Teer JK, DeNicola GM, Permuth JB, Fleming JB. Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas. Lab Invest. 2021 Feb.101(2):204-217. Pubmedid: 33037322. Pmcid: PMC7855435.
  • Di Pompo G, Errani C, Gillies R, Mercatali L, Ibrahim T, Tamanti J, Baldini N, Avnet S. Acid-Induced Inflammatory Cytokines in Osteoblasts: A Guided Path to Osteolysis in Bone Metastasis. Front Cell Dev Biol. 2021 May.9:678532. Pubmedid: 34124067. Pmcid: PMC8194084.
  • Dibs K, Sim AJ, Peñagaricano JA, Latifi K, Garcia GA, Peters JA, Nieder ML, Kim S, Robinson TJ. Gonadal-sparing total body irradiation with the use of helical tomotherapy for nonmalignant indications. Rep Pract Oncol Radiother. 2021 Feb.26(1):153-158. Pubmedid: 34046227. Pmcid: PMC8149136.
  • Hamdi Y, Abdeljaoued-Tej I, Zatchi AA, Abdelhak S, Boubaker S, Brown JS, Benkahla A. Cancer in Africa: The Untold Story. Front Oncol. 2021 Apr.11:650117. Pubmedid: 33937056. Pmcid: PMC8082106.
  • Bukkuri A, Andor N, Darcy IK. Applications of Topological Data Analysis in Oncology. Front Artif Intell. 2021 Apr.4:659037. Pubmedid: 33928240. Pmcid: PMC8076640.
  • Law V, Baldwin M, Ramamoorthi G, Kodumudi K, Tran N, Smalley I, Duckett D, Kalinski P, Czerniecki B, Smalley KSM, Forsyth PA. A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease. J Vis Exp. 2021 Jan.(167). Pubmedid: 33586709.
  • Malachowski SJ, Moy A, Messina J, Chen YA, Sun J, Sokol L, Seminario-Vidal L. Mapping cutaneous T-cell lymphoma in the state of Florida: A retrospective exploratory spatial analysis of incidence patterns. J Am Acad Dermatol. 2021 Jan. Pubmedid: 33476732.
  • Salvioli M, Dubbeldam J, Staňková K, Brown JS. Fisheries management as a Stackelberg Evolutionary Game: Finding an evolutionarily enlightened strategy. PLoS One. 2021 Jan.16(1):e0245255. Pubmedid: 33471815. Pmcid: PMC7817040.
  • Ruiz-Deya G, Matta J, Encarnación-Medina J, Ortiz-Sanchéz C, Dutil J, Putney R, Berglund A, Dhillon J, Kim Y, Park JY. Differential DNA Methylation in Prostate Tumors from Puerto Rican Men. Int J Mol Sci. 2021 Jan.22(2). Pubmedid: 33450964. Pmcid: PMC7828429.
  • Damaghi M, West J, Robertson-Tessi M, Xu L, Ferrall-Fairbanks MC, Stewart PA, Persi E, Fridley BL, Altrock PM, Gatenby RA, Sims PA, Anderson ARA, Gillies RJ. The harsh microenvironment in early breast cancer selects for a Warburg phenotype. Proc Natl Acad Sci U S A. 2021 Jan.118(3). Pubmedid: 33452133. Pmcid: PMC7826394.
  • Aiderus A, Contreras-Sandoval AM, Meshey AL, Newberg JY, Ward JM, Swing DA, Copeland NG, Jenkins NA, Mann KM, Mann MB. Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation. Cancers (Basel). 2021 Jan.13(2). Pubmedid: 33435458. Pmcid: PMC7827284.
  • Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Response to Mistry. Nat Commun. 2021 Jan.12(1):329. Pubmedid: 33436553. Pmcid: PMC7804311.
  • Tunali I, Gillies RJ, Schabath MB. Application of Radiomics and Artificial Intelligence for Lung Cancer Precision Medicine. Cold Spring Harb Perspect Med. 2021 Jan. Pubmedid: 33431509.
  • Hodge JM, Coghill AE, Kim Y, Bender N, Smith-Warner SA, Gapstur S, Teras LR, Grimsrud TK, Waterboer T, Egan KM. Toxoplasma gondii infection and the risk of adult glioma in two prospective studies. Int J Cancer. 2021 Jan. Pubmedid: 33427315.
  • Gibbs JD, Ma S, Kim A, Seminario-Vidal L, Sokol L, Zhang H, Zhang X, Sagatys E, Chen PL, Messina JL. Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma. Oncol Rep. 2021 Jan.45(1):349-358. Pubmedid: 33416132.
  • Kang YP, Mockabee-Macias A, Jiang C, Falzone A, Prieto-Farigua N, Stone E, Harris IS, DeNicola GM. Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis. Cell Metab. 2021 Jan.33(1):174-189.e7. Pubmedid: 33357455. Pmcid: PMC7839835.
  • Edwards J, Marusyk A, Basanta D. Selection-driven tumor evolution with public goods leads to patterns of clonal expansion consistent with neutral growth. iScience. 2021 Jan.24(1):101901. Pubmedid: 33364589. Pmcid: PMC7753957.
  • Tavakoli F, Sartakhti JS, Manshaei MH, Basanta D. Cancer immunoediting: A game theoretical approach. In Silico Biol. 2021.14(1-2):1-12. Pubmedid: 33216021. Pmcid: PMC8203245.
  • Walker SA, Pham A, Nizzero S, Kim M, Riter B, Bletz J, Judge S, Phillips B, Noble D, Murray D, Wetzel E, Samson S, McMahon M, Flink C, Couch J, Tomlin C, Swanson K, Anderson ARA, Odde D, Shen H, Hughes S, Zahir N, Enderling H, Wolfram J. Education and Outreach in Physical Sciences in Oncology. Trends Cancer. 2021 Jan.7(1):3-9. Pubmedid: 33168416. Pmcid: PMC7895467.
  • Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Reply By Authors. J Urol. 2021 Jan.205(1):108. Pubmedid: 33095102.
  • Hajiran A, Zemp L, Aydin AM, Cheryian SK, Pow-Sang JM, Chahoud J, Spiess PE. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urol Oncol. 2021 Jan.39(1):72.e1-72.e5. Pubmedid: 33036902.
  • Awasthi S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, Kensler KH, Serna AN, Vidal AC, You S, Freeman MR, Davicioni E, Liu Y, Karnes JR, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk SP, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2021 Jan.27(1):320-329. Pubmedid: 33037017. Pmcid: PMC8042600.
  • Ibrahim-Hashim A, Luddy K, Abrahams D, Enriquez-Navas P, Damgaci S, Yao J, Chen T, Bui MM, Gillies RJ, O'Farrelly C, Richards CL, Brown JS, Gatenby RA. Artificial selection for host resistance to tumour growth and subsequent cancer cell adaptations: an evolutionary arms race. Brit J Cancer. 2021 Jan.124(2):455-465. Pubmedid: 33024265. Pmcid: PMC7852689.
  • Liu SW, Woody NM, Wei W, Appachi S, Contrera KJ, Tsai JC, Ghanem AI, Matia B, Joshi NP, Geiger JL, Ku JA, Burkey BB, Scharpf J, Prendes BL, Caudell JJ, Dunlap NE, Adelstein DJ, Porceddu S, Liu H, Siddiqui F, Lee NY, Koyfman S, Lamarre ED. Evaluating compliance with process-related quality metrics and survival in oral cavity squamous cell carcinoma: Multi-institutional oral cavity collaboration study. Head Neck. 2021 Jan.43(1):60-69. Pubmedid: 32918373.
  • Zhao Y, Amorrortu RP, Fenske NA, Cherpelis B, Messina JL, Sondak VK, Giuliano AR, Schell MJ, Waterboer T, Pawlita M, McKay-Chopin S, Gheit T, Tommasino M, Rollison DE. Cutaneous viral infections associated with ultraviolet radiation exposure. Int J Cancer. 2021 Jan.148(2):448-458. Pubmedid: 32818302. Pmcid: PMC7754468.
  • Dominello MM, Sanders T, Anscher M, Bayouth J, Brock KK, Carlson DJ, Hugo G, Joseph S, Knisely J, Mendonca MS, Mian OY, Moros EG, Singh AK, Yu JB. Responses to the 2018 and 2019 "One Big Discovery" Question: ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology…Where Are We Headed?. Int J Radiat Oncol Biol Phys. 2021 Jan.109(1):38-40. Pubmedid: 32798605.
  • Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan.205(1):100-108. Pubmedid: 32783489. Pmcid: PMC7864376.
  • Hernandez-Prera J, Valderrabano P, Creed J, de la Iglesia JV, Slebos R, Centeno BA, Tarasova V, Hallanger-Johnson J, Veloski C, Otto KJ, Wenig BM, Yoder S, Lam C, Park DS, Anderson AR, Raghunand N, Berglund A, Caudell J, Gerke TA, Chung CH. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2021 Jan.31(1):36-49. Pubmedid: 32689909. Pmcid: PMC7864115.
  • Enderling H, Wolkenhauer O. Are all models wrong?. Comput Syst Oncol. 2020 Dec.1(1). Pubmedid: 33585835. Pmcid: PMC7880041.
  • Ordway B, Tomaszewski M, Byrne S, Abrahams D, Swietach P, Gillies RJ, Damaghi M. Targeting of Evolutionarily Acquired Cancer Cell Phenotype by Exploiting pHi-Metabolic Vulnerabilities. Cancers (Basel). 2020 Dec.13(1). Pubmedid: 33379345. Pmcid: PMC7795337.
  • Mo Q, Li R, Adeegbe DO, Peng G, Chan KS. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Commun Biol. 2020 Dec.3(1):784. Pubmedid: 33335285. Pmcid: PMC7746703.
  • West J, Ma Y, Kaznatcheev A, Anderson ARA. IsoMaTrix: a framework to visualize the isoclines of matrix games and quantify uncertainty in structured populations. Bioinformatics. 2020 Dec. Pubmedid: 33325501. Pmcid: PMC8016459.
  • Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2020 Dec. Pubmedid: 33303244.
  • Wang C, Zhang L, Ke L, Ding W, Jiang S, Li D, Narita Y, Hou I, Liang J, Li S, Xiao H, Gottwein E, Kaye KM, Teng M, Zhao B. Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors. Nat Commun. 2020 Dec.11(1):6318. Pubmedid: 33298918. Pmcid: PMC7726151.
  • Damaghi M, Mori H, Byrne S, Xu L, Chen T, Johnson J, Gallant ND, Marusyk A, Borowsky AD, Gillies RJ. Collagen production and niche engineering: A novel strategy for cancer cells to survive acidosis in DCIS and evolve. Evol Appl. 2020 Dec.13(10):2689-2703. Pubmedid: 33294017. Pmcid: PMC7691473.
  • Wei L, Cui C, Xu J, Kaza R, El Naqa I, Dewaraja YK. Tumor response prediction in 90Y radioembolization with PET-based radiomics features and absorbed dose metrics. EJNMMI Phys. 2020 Dec.7(1):74. Pubmedid: 33296050. Pmcid: PMC7726084.
  • Cunningham J, Thuijsman F, Peeters R, Viossat Y, Brown J, Gatenby R, Staňková K. Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer. PLoS One. 2020 Dec.15(12):e0243386. Pubmedid: 33290430. Pmcid: PMC7723267.
  • Pienta KJ, Hammarlund EU, Austin RH, Axelrod R, Brown JS, Amend SR. Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy. Semin Cancer Biol. 2020 Dec. Pubmedid: 33276091.
  • Meyer JM, Lee E, Celli A, Park K, Cho R, Lambert W, Pitchford M, Gordon M, Tsai K, Cleaver J, Arron ST, Mauro TM. CERKL is Upregulated in Cutaneous Squamous Cell Carcinoma and Maintains Cellular Sphingolipids and Resistance to Oxidative Stress. Br J Dermatol. 2020 Dec. Pubmedid: 33270220. Pmcid: PMC8172666.
  • Rishi A, Zhang GG, Yuan Z, Sim AJ, Song EY, Moros EG, Tomaszewski MR, Latifi K, Pimiento JM, Fontaine JP, Mehta R, Harrison LB, Hoffe SE, Frakes JM. Pretreatment CT and 18 F-FDG PET-based radiomic model predicting pathological complete response and loco-regional control following neoadjuvant chemoradiation in oesophageal cancer. J Med Imaging Radiat Oncol. 2020 Dec.65(1):102-111. Pubmedid: 33258556.
  • Kirby J, Prior F, Petrick N, Hadjiski L, Farahani K, Drukker K, Kalpathy-Cramer J, Glide-Hurst C, El Naqa I. Introduction to special issue on datasets hosted in The Cancer Imaging Archive (TCIA). Med Phys. 2020 Dec.47(12):6026-6028. Pubmedid: 33202038.
  • Makin DF, Kotler BP, Brown JS, Garrido M, Menezes JFS. The Enemy Within: How Does a Bacterium Inhibit the Foraging Aptitude and Risk Management Behavior of Allenby's Gerbils?. Am Nat. 2020 Dec.196(6):717-729. Pubmedid: 33211558.
  • Bellan DL, Biscaia SMP, Rossi GR, Cristal AM, Gonçalves JP, Oliveira CC, Simas FF, Sabry DA, Rocha HAO, Franco CRC, Chammas R, Gillies RJ, Trindade ES. Green does not always mean go: A sulfated galactan from Codium isthmocladum green seaweed reduces melanoma metastasis through direct regulation of malignancy features. Carbohydr Polym. 2020 Dec.250:116869. Pubmedid: 33049818.
  • Halloway A, Malone MA, Brown JS. Unstable population dynamics in obligate co-operators. Theor Popul Biol. 2020 Dec.136:1-11. Pubmedid: 33031837.
  • Park DS, Luddy KA, Robertson-Tessi M, O'Farrelly C, Gatenby RA, Anderson ARA. Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies. Cancer Res. 2020 Dec.80(23):5147-5154. Pubmedid: 32934022.
  • Gillies RJ, Schabath MB. Radiomics Improves Cancer Screening and Early Detection. Cancer Epidemiol Biomarkers Prev. 2020 Dec.29(12):2556-2567. Pubmedid: 32917666.
  • Carr MJ, Sun J, Kroon HM, Miura JT, Beasley GM, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Kim Y, Naqvi SMH, Kirichenko DA, Potdar A, Daou H, Mullen D, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Smithers BM, Coventry BJ, Tyler DS, Thompson JF, Zager JS. Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. Ann Surg Oncol. 2020 Dec.27(13):5107-5118. Pubmedid: 32918177. Pmcid: PMC7674259.
  • Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al-Ali N, Lancet JE, Cleveland JL, Padron E, List AF. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020 Dec.136(24):2812-2823. Pubmedid: 32730593. Pmcid: PMC7731792.
  • Mu W, Liang Y, Hall LO, Tan Y, Balagurunathan Y, Wenham R, Wu N, Tian J, Gillies RJ. 18F-FDG PET/CT Habitat Radiomics Predicts Outcome of Patients with Cervical Cancer Treated with Chemoradiotherapy. Radiol Artif Intell. 2020 Nov.2(6):e190218. Pubmedid: 33937845. Pmcid: PMC8082355.
  • Peacock J, Sikariam D, Maun-Garcia L, Javedan K, Yamoah K, Parikh N. A Proof-of-Concept Study on the Use of Prostate Artery Embolization Before Definitive Radiation Therapy in Prostate Cancer. Adv Radiat Oncol. 2021 May.6(3):100619. Pubmedid: 33748542. Pmcid: PMC7966837.
  • Sondak VK, Messina JL, Tarhini AA. Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma. J Am Coll Surg. 2020 Nov.231(5):554-556. Pubmedid: 33491653.
  • Sharma V, Wright KL, Epling-Burnette PK, Reuther GW. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms. Front Immunol. 2020 Nov.11:604142. Pubmedid: 33329600. Pmcid: PMC7734315.
  • Makovich Z, Logemann J, Chen L, Mhaskar R, Choi J, Parikh N, El-Haddad G, Kis B. Liver tumor ablation in difficult locations: Microwave ablation of perivascular and subdiaphragmatic hepatocellular carcinoma. Clin Imaging. 2020 Nov.71:170-177. Pubmedid: 33285405.
  • Lu H, Kim J, Qi J, Li Q, Liu Y, Schabath MB, Ye Z, Gillies RJ, Balagurunathan Y. Multi-Window CT Based Radiological Traits for Improving Early Detection in Lung Cancer Screening. Cancer Manag Res. 2020 Nov.12:12225-12238. Pubmedid: 33273859. Pmcid: PMC7707434.
  • Gatenby RA, Brown JS. The Evolution and Ecology of Resistance in Cancer Therapy. Cold Spring Harb Perspect Med. 2020 Nov.10(11). Pubmedid: 33139405. Pmcid: PMC7605238.
  • Gatenby R, Brown J. Retraction: The Evolution and Ecology of Resistance in Cancer Therapy. Cold Spring Harb Perspect Med. 2020 Nov.10(11). Pubmedid: 33139406. Pmcid: PMC7605237.
  • Shi Y, Sang P, Lu J, Higbee P, Chen L, Yang L, Odom T, Daughdrill G, Chen J, Cai J. Rational Design of Right-Handed Heterogeneous Peptidomimetics as Inhibitors of Protein-Protein Interactions. J Med Chem. 2020 Nov.63(21):13187-13196. Pubmedid: 33140956. Pmcid: PMC8170677.
  • Zon L, Gomes AP, Cance WG, Ribas A, Tuveson D, Postel-Vinay S, Massard C, Barlési F. Impact of COVID-19 Pandemic on Cancer Research. Cancer Cell. 2020 Nov.38(5):591-593. Pubmedid: 33086030. Pmcid: PMC7543995.
  • Berglund A, Amankwah EK, Kim YC, Spiess PE, Sexton WJ, Manley B, Park HY, Wang L, Chahoud J, Chakrabarti R, Yeo CD, Luu HN, Pietro GD, Parker A, Park JY. Influence of gene expression on survival of clear cell renal cell carcinoma. Cancer Med. 2020 Nov.9(22):8662-8675. Pubmedid: 32986937. Pmcid: PMC7666730.
  • Kim KB, Kim Y, Rivard CJ, Kim DW, Park KS. FGFR1 Is Critical for RBL2 Loss-Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer. Cancer Res. 2020 Nov.80(22):5051-5062. Pubmedid: 32973083. Pmcid: PMC7669587.
  • Tichacek CJ, Tafreshi NK, Kil H, Engelman RW, Doligalski ML, Budzevich MM, Gage KL, McLaughlin ML, Wadas TJ, Silva A, Moros E, Morse DL. Biodistribution and Multicompartment Pharmacokinetic Analysis of a Targeted α Particle Therapy. Mol Pharm. 2020 Nov.17(11):4180-4188. Pubmedid: 32960613.
  • Kimmel GJ, Dane M, Heiser LM, Altrock PM, Andor N. Integrating Mathematical Modeling with High-Throughput Imaging Explains How Polyploid Populations Behave in Nutrient-Sparse Environments. Cancer Res. 2020 Nov.80(22):5109-5120. Pubmedid: 32938640. Pmcid: PMC7671819.
  • Grimes DR, Jansen M, Macauley RJ, Scott JG, Basanta D. Evidence for hypoxia increasing the tempo of evolution in glioblastoma. Brit J Cancer. 2020 Nov.123(10):1562-1569. Pubmedid: 32848201. Pmcid: PMC7653934.
  • Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol. 2020 Nov.17(11):675-686. Pubmedid: 32699310.
  • Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist. 2020 Nov.25(11):e1655-e1662. Pubmedid: 32701199. Pmcid: PMC7648334.
  • McGuire JJ, Nerlakanti N, Lo CH, Tauro M, Utset-Ward TJ, Reed DR, Lynch CC. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma. Int J Cancer. 2020 Nov.147(10):2811-2823. Pubmedid: 32599665. Pmcid: PMC7787271.
  • Napoli M, Flores ER. The p53 family reaches the final frontier: the variegated regulation of the dark matter of the genome by the p53 family in cancer. RNA Biol. 2020 Nov.17(11):1636-1647. Pubmedid: 31910062. Pmcid: PMC7567494.
  • Ardaševa A, Anderson ARA, Gatenby RA, Byrne HM, Maini PK, Lorenzi T. Comparative study between discrete and continuum models for the evolution of competing phenotype-structured cell populations in dynamical environments. Phys Rev E. 2020 Oct.102(4-1):042404. Pubmedid: 33212726.
  • Shanks A, Laun J, Holstein A, Varshney S, Messina J, Cruse CW. A rare concurrence of Muir-Torre-associated sebaceous carcinoma in the setting of a lipedematous scalp. Case Reports Plast Surg Hand Surg. 2020 Oct.7(1):124-129. Pubmedid: 33178881. Pmcid: PMC7594736.
  • Shields M, Mo Q, Armitage M, Sharpe SC, Costa RLB. A systematic review and meta-analysis of selected toxicity endpoints of alpelisib. Oncotarget. 2020 Oct.11(42):3793-3799. Pubmedid: 33144920. Pmcid: PMC7584237.
  • Farha M, Jairath NK, Lawrence TS, El Naqa I. Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma. JCO Clin Cancer Inform. 2020 Oct.4:1002-1013. Pubmedid: 33136432. Pmcid: PMC7713549.
  • Taylor NJ, Gaynanova I, Eschrich SA, Welsh EA, Garrett TJ, Beecher C, Sharma R, Koomen JM, Smalley KSM, Messina JL, Kanetsky PA. Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment. PLoS One. 2020 Oct.15(10):e0240849. Pubmedid: 33108391. Pmcid: PMC7591037.
  • Zhang Y, Jiang C, Trudeau SJ, Narita Y, Zhao B, Teng M, Guo R, Gewurz BE. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation. MBio. 2020 Oct.11(5). Pubmedid: 33109754. Pmcid: PMC7593962.
  • DeBlasi JM, DeNicola GM. Dissecting the Crosstalk between NRF2 Signaling and Metabolic Processes in Cancer. Cancers (Basel). 2020 Oct.12(10). Pubmedid: 33080927. Pmcid: PMC7603127.
  • Zahedi K, Brooks M, Barone S, Rahmati N, Murray Stewart T, Dunworth M, Destefano-Shields C, Dasgupta N, Davidson S, Lindquist DM, Fuller CE, Smith RD, Cleveland JL, Casero RA, Soleimani M. Ablation of polyamine catabolic enzymes provokes Purkinje cell damage, neuroinflammation, and severe ataxia. J Neuroinflamm. 2020 Oct.17(1):301. Pubmedid: 33054763. Pmcid: PMC7559641.
  • Napoli M, Li X, Ackerman HD, Deshpande AA, Barannikov I, Pisegna MA, Bedrosian I, Mitsch J, Quinlan P, Thompson A, Rajapakshe K, Coarfa C, Gunaratne PH, Marchion DC, Magliocco AM, Tsai KY, Flores ER. Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nat Commun. 2020 Oct.11(1):5156. Pubmedid: 33056990. Pmcid: PMC7561725.
  • Nguyen TN, Rajapakshe K, Nicholas C, Tordesillas L, Ehli EA, Davis CM, Coarfa C, Flores ER, Dickinson SE, Curiel-Lewandrowski C, Tsai KY. Integrative transcriptomic analysis for linking acute stress responses to squamous cell carcinoma development. Sci Rep. 2020 Oct.10(1):17209. Pubmedid: 33057049. Pmcid: PMC7560606.
  • Mu W, Jiang L, Zhang J, Shi Y, Gray JE, Tunali I, Gao C, Sun Y, Tian J, Zhao X, Sun X, Gillies RJ, Schabath MB. Non-invasive decision support for NSCLC treatment using PET/CT radiomics. Nat Commun. 2020 Oct.11(1):5228. Pubmedid: 33067442. Pmcid: PMC7567795.
  • Lakatos E, Williams MJ, Schenck RO, Cross WCH, Househam J, Zapata L, Werner B, Gatenbee C, Robertson-Tessi M, Barnes CP, Anderson ARA, Sottoriva A, Graham TA. Evolutionary dynamics of neoantigens in growing tumors. Nat Genetics. 2020 Oct.52(10):1057-1066. Pubmedid: 32929288. Pmcid: PMC7610467.
  • Zlateva Y, Muir BR, El Naqa I, Seuntjens J. Step-size effect on calculated photon and electron beam Cherenkov-to-dose conversion factors. Phys Med. 2020 Oct.78:32-37. Pubmedid: 32916557.
  • Thomson DJ, Yom SS, Saeed H, El Naqa I, Ballas L, Bentzen SM, Chao ST, Choudhury A, Coles CE, Dover L, Guadagnolo BA, Guckenberger M, Hoskin P, Jabbour SK, Katz MS, Mukherjee S, Rembielak A, Sebag-Montefiore D, Sher DJ, Terezakis SA, Thomas TV, Vogel J, Estes C. Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. Int J Radiat Oncol Biol Phys. 2020 Oct.108(2):379-389. Pubmedid: 32798063. Pmcid: PMC7834196.
  • Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 Oct.27(10):882-889. Pubmedid: 32767444.
  • Combs JA, DeNicola GM. The smell of death and deCYStiny: polyamines play the hero. Nat Metab. 2020 Oct.2(10):995-996. Pubmedid: 32747795.
  • Thomson DJ, Palma D, Guckenberger M, Balermpas P, Beitler JJ, Blanchard P, Brizel D, Budach W, Caudell J, Corry J, Corvo R, Evans M, Garden AS, Giralt J, Gregoire V, Harari PM, Harrington K, Hitchcock YJ, Johansen J, Kaanders J, Koyfman S, Langendijk JA, Le QT, Lee N, Margalit D, Mierzwa M, Porceddu S, Soong YL, Sun Y, Thariat J, Waldron J, Yom SS. Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiother Oncol. 2020 Oct.151:314-321. Pubmedid: 32730830. Pmcid: PMC7384409.
  • Oraiqat I, Zhang W, Litzenberg D, Lam K, Ba Sunbul N, Moran J, Cuneo K, Carson P, Wang X, El Naqa I. An ionizing radiation acoustic imaging (iRAI) technique for real-time dosimetric measurements for FLASH radiotherapy. Med Phys. 2020 Oct.47(10):5090-5101. Pubmedid: 32592212. Pmcid: PMC7722001.
  • Huang J, Sachdeva M, Xu E, Robinson TJ, Luo L, Ma Y, Williams N, Lopez O, Cervia LD, Yuan F, Qin X, Zhang D, Owzar K, Gokgoz N, Seto A, Okada T, Singer S, Andrulis IL, Wunder J, Lazar AJ, Rubin BP, Pipho K, Mello SS, Giudice J, Kirsch DG. The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways. Mol Cancer Res. 2020 Oct.18(10):1534-1544. Pubmedid: 32561656. Pmcid: PMC7541426.
  • Lake PW, Kasting ML, Dean M, Fuzzell L, Hudson J, Carvajal R, Reed DR, Quinn GP, Vadaparampil ST. Exploring patient and provider perspectives on the intersection between fertility, genetics, and family building. Support Care Cancer. 2020 Oct.28(10):4833-4845. Pubmedid: 31982959. Pmcid: PMC7810131.
  • Parikh N, Acharya V, Bhatia S. Prostate Artery Embolization - Adverse Events and Peri-Procedural Management. Tech Vasc Interv Radiol. 2020 Sep.23(3):100692. Pubmedid: 33308533.
  • Wirsing AJ, Heithaus MR, Brown JS, Kotler BP, Schmitz OJ. The context dependence of non-consumptive predator effects. Ecol Lett. 2021 Jan.24(1):113-129. Pubmedid: 32990363.
  • Combs JA, DeNicola GM. Publisher Correction: The smell of death and deCYStiny: polyamines play the hero. Nat Metab. 2020 Oct.2(10):1180. Pubmedid: 32973367.
  • Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol. 2020 Sep. Pubmedid: 32936333. Pmcid: PMC8101019.
  • Stewart PA, Welsh EA, Fang B, Izumi V, Mesa T, Zhang C, Yoder S, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Avedon M, Wloch M, Fournier M, Fellows KM, Francis JM, Saller JJ, Boyle TA, Chen YA, Haura EB, Teer JK, Eschrich SA, Koomen JM. Managing a Large-Scale Multiomics Project: A Team Science Case Study in Proteogenomics. Methods Mol Biol. 2020 Sep.2194:187-221. Pubmedid: 32926368. Pmcid: PMC7771375.
  • Min S, Oyelakin A, Gluck C, Bard JE, Song EC, Smalley K, Che M, Flores E, Sinha S, Romano RA. p63 and Its Target Follistatin Maintain Salivary Gland Stem/Progenitor Cell Function through TGF-β/Activin Signaling. iScience. 2020 Sep.23(9):101524. Pubmedid: 32932139. Pmcid: PMC7498843.
  • Frieling JS, Li T, Tauro M, Lynch CC. Prostate cancer-derived MMP-3 controls intrinsic cell growth and extrinsic angiogenesis. Neoplasia. 2020 Oct.22(10):511-521. Pubmedid: 32896761. Pmcid: PMC7481881.
  • Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Ne. 2020 Sep.18(9):1160-1170. Pubmedid: 32886895.
  • Sang P, Shi Y, Lu J, Chen L, Yang L, Borcherds W, Abdulkadir S, Li Q, Daughdrill G, Chen J, Cai J. Correction to α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions. J Med Chem. 2020 Sep.63(17):10087. Pubmedid: 32822169. Pmcid: PMC7853636.
  • Gomes AP, Ilter D, Low V, Endress JE, Fernández-García J, Rosenzweig A, Schild T, Broekaert D, Ahmed A, Planque M, Elia I, Han J, Kinzig C, Mullarky E, Mutvei AP, Asara J, de Cabo R, Cantley LC, Dephoure N, Fendt SM, Blenis J. Age-induced accumulation of methylmalonic acid promotes tumour progression. Nature. 2020 Sep.585(7824):283-287. Pubmedid: 32814897. Pmcid: PMC7785256.
  • Wang X, Yu X, Krauthammer M, Hugo W, Duan C, Kanetsky PA, Teer JK, Thompson ZJ, Kalos D, Tsai KY, Smalley KSM, Sondak VK, Chen YA, Conejo-Garcia JR. The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. Cancer Epidemiol Biomarkers Prev. 2020 Sep.29(9):1792-1799. Pubmedid: 32611582. Pmcid: PMC7483810.
  • Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol. 2020 Sep.78(3):387-399. Pubmedid: 32143924. Pmcid: PMC7771323.
  • Bleicher SS, Kotler BP, Downs CJ, Brown JS. Intercontinental test of constraint-breaking adaptations: Testing behavioural plasticity in the face of a predator with novel hunting strategies. J Anim Ecol. 2020 Aug.89(8):1837-1850. Pubmedid: 32271948.
  • Maghami E, Ismaila N, Alvarez A, Chernock R, Duvvuri U, Geiger J, Gross N, Haughey B, Paul D, Rodriguez C, Sher D, Stambuk HE, Waldron J, Witek M, Caudell J. Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline. J Clin Oncol. 2020 Aug.38(22):2570-2596. Pubmedid: 32324430.
  • Hesterberg RS, Beatty MS, Han Y, Fernandez MR, Akuffo AA, Goodheart WE, Yang C, Chang S, Colin C, Alontaga AY, McDaniel J, Mailloux AW, Billington JMR, Yue L, Russell S, Gillies RJ, Yun SY, Ayaz M, Lawrence NJ, Lawrence H, Yu XZ, Fu J, Darville LN, Koomen JM, Ren X, Messina J, Jiang K, Garrett TJ, Rajadhyaksha A, Cleveland JL, Epling-Burnette PK. Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes. Blood. 2020 Aug.136(7):857-870. Pubmedid: 32403132. Pmcid: PMC7426646.
  • Guo R, Zhang Y, Teng M, Jiang C, Schineller M, Zhao B, Doench JG, O'Reilly RJ, Cesarman E, Giulino-Roth L, Gewurz BE. DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. Nat Microbiol. 2020 Aug.5(8):1051-1063. Pubmedid: 32424339. Pmcid: PMC7462085.
  • Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman SM, Sansil SS, Grant W, Monastyrskyi A, McDonald P, Roush WR, Teng M, Duckett D. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. Mol Cancer Ther. 2020 Aug.19(8):1623-1635. Pubmedid: 32430484. Pmcid: PMC7415672.
  • Hajiran A, Pow-Sang J. Editorial Comment. J Urol. 2020 Aug.204(2):266. Pubmedid: 32437261.
  • Subramonian D, Phanhthilath N, Rinehardt H, Flynn S, Huo Y, Zhang J, Messer K, Mo Q, Huang S, Lesperance J, Zage PE. Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. Brit J Cancer. 2020 Aug.123(4):568-579. Pubmedid: 32457362. Pmcid: PMC7434894.
  • Pursley J, El Naqa I, Sanford NN, Noe B, Wo JY, Eyler CE, Hwang M, Brock KK, Yeap BY, Wolfgang JA, Hong TS, Grassberger C. Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation. Int J Radiat Oncol Biol Phys. 2020 Aug.107(5):986-995. Pubmedid: 32353390. Pmcid: PMC7381375.
  • Sang P, Shi Y, Higbee P, Wang M, Abdulkadir S, Lu J, Daughdrill GW, Chen J, Cai J. Rational Design and Synthesis of Right-Handed d-Sulfono-γ-AApeptide Helical Foldamers as Potent Inhibitors of Protein-Protein Interactions. J Org Chem. 2020 Aug.85(16):10552-10560. Pubmedid: 32700908. Pmcid: PMC8204676.
  • Moore CE, Monforte H, Teer JK, Zhang Y, Yoder S, Brohl AS, Reed D. TRIM28 congenital predisposition to Wilms' tumor: novel mutations and presentation in a sibling pair. Cold Spring Harb Mol Case Stud. 2020 Aug.6(4). Pubmedid: 32699065. Pmcid: PMC7476416.
  • Zahir N, Sun R, Gallahan D, Gatenby RA, Curtis C. Characterizing the ecological and evolutionary dynamics of cancer. Nat Genetics. 2020 Aug.52(8):759-767. Pubmedid: 32719518.
  • Wu H, Estrella V, Beatty M, Abrahams D, El-Kenawi A, Russell S, Ibrahim-Hashim A, Longo DL, Reshetnyak YK, Moshnikova A, Andreev OA, Luddy K, Damaghi M, Kodumudi K, Pillai SR, Enriquez-Navas P, Pilon-Thomas S, Swietach P, Gillies RJ. T-cells produce acidic niches in lymph nodes to suppress their own effector functions. Nat Commun. 2020 Aug.11(1):4113. Pubmedid: 32807791. Pmcid: PMC7431837.
  • Kuykendall AT, Horvat NP, Pandey G, Komrokji R, Reuther GW. Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers (Basel). 2020 Aug.12(8). Pubmedid: 32823910. Pmcid: PMC7464183.
  • Fang B, Izumi V, Rix LLR, Welsh E, Pike I, Reuther GW, Haura EB, Rix U, Koomen JM. Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator Approach. Proteomics. 2020 Dec.20(24):e2000116. Pubmedid: 32865326. Pmcid: PMC7771371.
  • Damgaci S, Enriquez-Navas PM, Pilon-Thomas S, Guvenis A, Gillies RJ, Ibrahim-Hashim A. Immunotherapy on acid: opportunities and challenges. Eur J Clin Nutr. 2020 Aug.74(Suppl 1):3-6. Pubmedid: 32873950. Pmcid: PMC7777416.
  • Gatenby RA, Avdieiev S, Tsai KY, Brown JS. Integrating genetic and nongenetic drivers of somatic evolution during carcinogenesis: The biplane model. Evol Appl. 2020 Aug.13(7):1651-1659. Pubmedid: 32952610. Pmcid: PMC7484850.
  • Pienta KJ, Hammarlund EU, Axelrod R, Brown JS, Amend SR. Poly-aneuploid cancer cells promote evolvability, generating lethal cancer. Evol Appl. 2020 Aug.13(7):1626-1634. Pubmedid: 32952609. Pmcid: PMC7484876.